Episode

Episode 487: ASCO GU 2026 recap

Podcast: The Uromigos
Published: Mar 8, 2026
Duration seconds: 3370
Processing state: not_requested
Canonical source: https://podcasters.spotify.com/pod/show/the-uromigos/episodes/Episode-487-ASCO-GU-2026-recap-e3g4fgn
Audio: https://anchor.fm/s/13347ea8/podcast/play/116587479/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-2-8%2F419556150-44100-2-82199219f5d99.m4a
JSON: /v1/public/podcasts/the-uromigos-1214845/episodes/episode-487-asco-gu-2026-recap
Markdown: /podcast/the-uromigos-1214845/episode-487-asco-gu-2026-recap.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-487-asco-gu-2026-recap/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-uromigos-1214845/episode-487-asco-gu-2026-recap.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Brian, Silke and Tom discusses the latest data and insights from ASCO GU 2026 across kidney, prostate, and bladder cancer, highlighting new therapies, trial results, and future directions in urologic oncology.